Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
Vitamins and minerals - Iron
Hutfless S, Jasper RA, Tilak A, et al
This is convenient for patients who prefer fewer injections compared to daily treatments like liraglutide (Victoza)
